Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge
Keywords: واکنش فاز اولیه; FcÉR1; eosinophils; allergy; mast cells; T cells; omalizumab; AUC; Area under the curve; BU; Biological units; EPR; Early-phase reaction; HDM; House dust mite; LAR; Late asthmatic reaction; LPR; Late-phase reaction; PA; AUC for allergen; PA-D; AUC for